Amplifed Dna Or Rna Probe Detection Of Severe Acute Respiratory Syndrome Coronavirus 2 (covid-19) Antigen in Maryland
Estimated using RAND 2024 commercial-to-Medicare ratios. Actual prices vary by insurer, plan, and facility.
Top Providers in Maryland
| Provider | Medicare | Services |
|---|---|---|
| Realtox Labs, Llc | $50.28 | 3.2K |
| Cirrus Dx, Inc. | $50.28 | 856 |
| Quest Diagnostics Incorporated Md | $50.28 | 673 |
Maryland Pricing in Context
In Maryland, CPT code 87635 (Amplifed Dna Or Rna Probe Detection Of Severe Acute Respiratory Syndrome Coronavirus 2 (covid-19) Antigen) carries an average Medicare payment of $50.18 — 0% above the national benchmark of $50.08. 432 providers across the state submitted claims for this procedure in 2023, performing 12.9K total services. Individual payments in MD ranged from N/A at the low end to N/A at the high end, reflecting differences in provider setting (office vs. facility), modifiers, and the specific geographic locality code applied within the state.
The average billed charge in Maryland is $120.19, which is the figure uninsured patients would most likely encounter before any negotiation or charity discount. Medicare, by statute, only reimburses the allowed amount — the balance between billed and paid is written off under provider participation agreements. Insured patients generally pay a negotiated rate that falls between these two figures; the exact amount depends on plan design, deductible status, and in-network participation. Because Maryland sits above the national Medicare average, commercial rates in the state may also run higher than the US median.
Using RAND 2024 commercial-to-Medicare ratios for Genetic/Molecular Test procedures, the estimated commercial insurance price in Maryland lands near $100.36, with self-pay cash prices typically around $70.69. Before scheduling, patients can request a Good Faith Estimate under the No Surprises Act, compare cash rates from hospital Machine-Readable Files, and confirm whether the provider is in-network with their specific plan. This page presents CMS reference data for informational use; it does not constitute medical or financial advice.
Frequently Asked Questions
How much does Amplifed Dna Or Rna Probe Detection Of Severe Acute Respiratory Syndrome Coronavirus 2 (covid-19) Antigen cost in Maryland?
The average Medicare payment for Amplifed Dna Or Rna Probe Detection Of Severe Acute Respiratory Syndrome Coronavirus 2 (covid-19) Antigen in Maryland is $50.18, which is 0% above the national average of $50.08. Providers in MD typically bill $120.19 for this procedure.
What does Amplifed Dna Or Rna Probe Detection Of Severe Acute Respiratory Syndrome Coronavirus 2 (covid-19) Antigen cost with insurance in Maryland?
With commercial insurance in Maryland, Amplifed Dna Or Rna Probe Detection Of Severe Acute Respiratory Syndrome Coronavirus 2 (covid-19) Antigen costs an estimated $100.36. Without insurance, the estimated cash price is $70.69. These estimates are based on RAND 2024 commercial-to-Medicare ratios and vary by insurer, plan, and facility.
How many providers perform Amplifed Dna Or Rna Probe Detection Of Severe Acute Respiratory Syndrome Coronavirus 2 (covid-19) Antigen in Maryland?
432 providers in Maryland billed Medicare for Amplifed Dna Or Rna Probe Detection Of Severe Acute Respiratory Syndrome Coronavirus 2 (covid-19) Antigen in 2023, performing 12.9K total services. Medicare payments ranged from N/A to N/A depending on the provider.
Is Amplifed Dna Or Rna Probe Detection Of Severe Acute Respiratory Syndrome Coronavirus 2 (covid-19) Antigen cheaper in Maryland than the national average?
No — Amplifed Dna Or Rna Probe Detection Of Severe Acute Respiratory Syndrome Coronavirus 2 (covid-19) Antigen costs 0% above the national average in Maryland. The state average Medicare payment is $50.18 compared to $50.08 nationally. Factors like local cost of living, provider competition, and regional Medicare fee schedules all influence state-level pricing.
Related Guides
Related Data Sources
Data from CMS Medicare Physician & Other Practitioners (2023).
Read our methodology — how this data is sourced, computed, and verified.